|
|
| |
| Most Discussed Stocks |
 |
|
|
|
| |
|
News |
| |
|
WILL THE FDA GIVE THE GREEN LIGHT T.... |
10/06/2008 |
|
Has the time come for Provenge, the prostate cancer vaccine developed by Dendreon, to be given marketing approval so it can save condemned metastatic prostate cancer patients’ lives? |
| |
|
PROGENICS: THE HIV DRUG LOOKS PROMI.... |
10/02/2008 |
|
|
| |
|
WE WILL BE ALL RIGHT |
09/25/2008 |
|
We gave you Sequenom and many other winners. Prohost will continue to do the same, hopefully without as much struggling against the greed of those who took advantage of the market deregulation to turn it into a vehicle for self-fulfillment of destructive prophesies at the expense of the serious investors.
We surely believe that America is capable of overcoming this crisis. Yet, our hope is in a reform that stops the greed that tarnished the market’s and America’s strong economy’s reputation.
We will be all right.
|
| |
|
SEQUENOM (SQNM): SUCCESS OF NON INV.... |
09/24/2008 |
|
The results are 100% without manipulation of the fetus and with a simple mother\'s blood test. |
| |
|
CYTRX COMPLETES ITS BUYOUT OF INNOV.... |
09/23/2008 |
|
Cytrx inherited the cancer drug tamibarotene, which has been approved in Japan for acute promyelocytic leukemia (APL). It also inherited three other drug candidates. Read about tamibarotene. Read also about the a stool test that shows successful results in diagnosing colorectal cancer. |
| |
|
|
| |
| |
| |
|
|
Stocks >> Stocks Details |
|
(PRIVATE COMPANY)
|
| |
|
NEURODEGENERATIVE RETINAL DISEASES |
|
|
|
ACUCELA
|
| |
|
Acucela is a private company focusing on eye
diseases, including neurodegenerative
retinal diseases (such as macular
degeneration), Stargardt's disease,
retinitis pigmentosa, and glaucoma. Acucela
uses long-lived, fully differentiated primary retinal neurons in its
proprietary pharmaceutical compound
screening systems to identify and develop safe, efficacious compounds. The OcuScreen™ service division
provides data generation on custom drug compounds for its customers. The firm
signed two alliances, which provide for upfront payments, milestone
payments, as well as royalties on sales of developed products. The Drug Discovery division discovers,
tests, and develops custom drug compounds for retinal eye diseases. Its pipeline has several candidates in
discovery and one compound in pre-clinical development. www.acucela.com |
| |
| |
| |
| |
| |
| |
|
|
|
|
